Merck is acquiring an antibiotic developer and manufacturer Cubist for $9.5 bln

Merck is acquiring an antibiotic developer and manufacturer Cubist for $9.5 bln. Cubist’s Cubicin (daptomycin) global sales exceeded $1 bln. in 2013. Cubicin is marketed by Novartis in Russia...

Read more

Ministry of Health developed formularies of medical devices available through the government guarantees program

Ministry of Health developed formularies of medical devices available through the government guarantees program. Ministry of Health committee made a decision to include 207 medical devices for implantation into human body. Three more medical devices will be available by prescription through the public social care program. Formularies…

Read more

Pfizer is acquiring two Baxter vaccines

Pfizer is acquiring two Baxter vaccines. The deal worth $635 mln will transfer rights as well as part of the factory in Austria where the vaccines are made. NeisVac-C helps protect against meningitis caused by group C meningococci. FSME-IMMUN/TicoVac is used to prevent tick-borne encephalitis. 120 million doses of the vaccine…

Read more

The cost to develop and win marketing approval for a new drug is $2.6 bn

The cost to develop and win marketing approval for a new drug is $2.6 bn. This data was obtained in a study by the Tufts Center of Drug Development. Analysis derived information from clinical trials of 106 drugs tested in 1995–2007. Average out-of-pocket cost is $1,4 bn. Additional time costs (expected returns that investors forego…

Read more

Allergan will escape hostile acquisition by Valeant by agreeing to be bought by Actavis

Allergan will escape hostile acquisition by Valeant by agreeing to be bought by Actavis. Canadian Valeant and its partner and investor, hedge fund manager William Ackman, do not consider a price of $66 billion paid by Actavis to be a fair value for an American Botox producer Allergan and are forced to end their pursuit. The failed…

Read more

R-pharm is acquiring 51% of SIA International

R-pharm is acquiring 51% of SIA International. After a recent death of the owner of SIA International Igor Rudinskiy his family is following through with the plan to sell 51% of shares to R-pharm group of companies. Rudinskiy’s family will continue to own 49% of shares, and SIA will keep most of its current management, but R-pharm…

Read more

EvaluatePharma® published its 2014 Orphan Drug Analysis

EvaluatePharma® published its 2014 Orphan Drug Analysis. The agency is forecasting orphan drug sales to grow from 90.16 bn USD in 2013 to 173.257 bn in 2020 (CAGR 2014 to 2020:+10%)/ The share of orphan drugs in sales of original drugs is predicted to reach 19.1% by 2020.
Bristol-Myers Squibb will…

Read more

Prix Galien Russia 2014 winners have been announced

Prix Galien Russia 2014 winners have been announced. Among international innovators, Pfizer was awarded the Best Biotech Product for its heptavalent conjugated pneumococcal vaccine Prevenar 13® and AstraZeneca — for Brilinta® (ticagrelor), an anti-antiplatelet superior to clopidogrel…

Read more